Comparative efficacies of ciprofloxacin and pefloxacin alone or in combination with fosfomycin in experimental endocarditis induced by multidrug-susceptible and -resistant Pseudomonas aeruginosa. 1995

Y Q Xiong, and G Potel, and J Caillon, and G Stephant, and F Jehl, and D Bugnon, and P Le Conte, and D Baron, and H Drugeon
Laboratoire d'Antibiologie Clinique et Expérimentale, Faculté de Médecine, Centre Hospitalier Universitaire, Nantes, France.

The in vivo efficacy of ciprofloxacin or pefloxacin alone or in combination with fosfomycin was evaluated in experimental aortic valve endocarditis induced in 133 rabbits by a multidrug-susceptible or multidrug-resistant strain of Pseudomonas aeruginosa. Therapy was initiated early (12 h after infection), when bacterial counts in aortic valve vegetations were relatively low, or late (48 h after infection), when vegetations contained a larger inoculum. Antibodies were administered as a continuous 24-h intravenous infusion. Mean steady-state levels of ciprofloxacin (64 mg/kg), pefloxacin (64 mg/kg), and fosfomycin (300 mg/kg) in serum were 2.5, 4.2, and 63.9 mg/liter, respectively. For the multidrug-susceptible strain, all regimens except pefloxacin alone significantly reduced the number of CFU per gram of vegetation versus controls, whether treatment was performed early or late. For the multidrug-resistant strain, none of the regimens showed differences from untreated controls, except ciprofloxacin-fosfomycin, which significantly reduced bacterial counts in vegetations compared with controls when therapy was begun early (4.1 +/- 1.1 log10 CFU/g of vegetation; P < 0.001 versus the control). These data suggest that combination of fosfomycin with ciprofloxacin or pefloxacin is more effective than ciprofloxacin or pefloxacin alone for the therapy of severe infections caused by multidrug-susceptible P. aeruginosa.

UI MeSH Term Description Entries
D011552 Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS. Infections, Pseudomonas,Pseudomonas aeruginosa Infection,Infection, Pseudomonas,Pseudomonas Infection,Pseudomonas aeruginosa Infections
D011817 Rabbits A burrowing plant-eating mammal with hind limbs that are longer than its fore limbs. It belongs to the family Leporidae of the order Lagomorpha, and in contrast to hares, possesses 22 instead of 24 pairs of chromosomes. Belgian Hare,New Zealand Rabbit,New Zealand Rabbits,New Zealand White Rabbit,Rabbit,Rabbit, Domestic,Chinchilla Rabbits,NZW Rabbits,New Zealand White Rabbits,Oryctolagus cuniculus,Chinchilla Rabbit,Domestic Rabbit,Domestic Rabbits,Hare, Belgian,NZW Rabbit,Rabbit, Chinchilla,Rabbit, NZW,Rabbit, New Zealand,Rabbits, Chinchilla,Rabbits, Domestic,Rabbits, NZW,Rabbits, New Zealand,Zealand Rabbit, New,Zealand Rabbits, New,cuniculus, Oryctolagus
D002939 Ciprofloxacin A broad-spectrum antimicrobial carboxyfluoroquinoline. Bay-09867,Ciprinol,Cipro,Ciprofloxacin Hydrochloride,Ciprofloxacin Hydrochloride Anhydrous,Ciprofloxacin Monohydrochloride Monohydrate,Anhydrous, Ciprofloxacin Hydrochloride,Bay 09867,Bay09867,Hydrochloride Anhydrous, Ciprofloxacin,Hydrochloride, Ciprofloxacin,Monohydrate, Ciprofloxacin Monohydrochloride,Monohydrochloride Monohydrate, Ciprofloxacin
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D004697 Endocarditis, Bacterial Inflammation of the ENDOCARDIUM caused by BACTERIA that entered the bloodstream. The strains of bacteria vary with predisposing factors, such as CONGENITAL HEART DEFECTS; HEART VALVE DISEASES; HEART VALVE PROSTHESIS IMPLANTATION; or intravenous drug use. Bacterial Endocarditides,Bacterial Endocarditis,Endocarditides, Bacterial
D005260 Female Females
D005578 Fosfomycin An antibiotic produced by Streptomyces fradiae. Phosphonomycin,Fosfomycin Trometamol Salt,Fosfomycin Tromethamine,Monuril,Phosphomycin,Tromethamine, Fosfomycin
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D015366 Pefloxacin A synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and gram-positive bacteria. 2589 R.B.,Abactal,Peflacine,Pefloxacin Mesylate,Pefloxacin Mesylate Dihydrate,Pefloxacine,Silver Pefloxacin,Dihydrate, Pefloxacin Mesylate,Mesylate Dihydrate, Pefloxacin,Mesylate, Pefloxacin,Pefloxacin, Silver,R.B., 2589
D018432 Drug Resistance, Multiple Simultaneous resistance to several structurally and functionally distinct drugs. Drug Resistance, Extensively,Extensively Drug Resistance,Extensively-Drug Resistance,Multidrug Resistance,Multi-Drug Resistance,Extensively Drug Resistances,Extensively-Drug Resistances,Multiple Drug Resistance,Resistance, Extensively Drug,Resistance, Extensively-Drug,Resistance, Multiple Drug

Related Publications

Y Q Xiong, and G Potel, and J Caillon, and G Stephant, and F Jehl, and D Bugnon, and P Le Conte, and D Baron, and H Drugeon
May 1996, International journal of antimicrobial agents,
Y Q Xiong, and G Potel, and J Caillon, and G Stephant, and F Jehl, and D Bugnon, and P Le Conte, and D Baron, and H Drugeon
May 2023, Journal of chemotherapy (Florence, Italy),
Y Q Xiong, and G Potel, and J Caillon, and G Stephant, and F Jehl, and D Bugnon, and P Le Conte, and D Baron, and H Drugeon
January 1989, Infection,
Y Q Xiong, and G Potel, and J Caillon, and G Stephant, and F Jehl, and D Bugnon, and P Le Conte, and D Baron, and H Drugeon
January 2000, Chemotherapy,
Y Q Xiong, and G Potel, and J Caillon, and G Stephant, and F Jehl, and D Bugnon, and P Le Conte, and D Baron, and H Drugeon
April 2016, Enfermedades infecciosas y microbiologia clinica,
Y Q Xiong, and G Potel, and J Caillon, and G Stephant, and F Jehl, and D Bugnon, and P Le Conte, and D Baron, and H Drugeon
June 1988, Antimicrobial agents and chemotherapy,
Y Q Xiong, and G Potel, and J Caillon, and G Stephant, and F Jehl, and D Bugnon, and P Le Conte, and D Baron, and H Drugeon
July 2019, The Journal of infectious diseases,
Y Q Xiong, and G Potel, and J Caillon, and G Stephant, and F Jehl, and D Bugnon, and P Le Conte, and D Baron, and H Drugeon
November 2023, Antibiotics (Basel, Switzerland),
Y Q Xiong, and G Potel, and J Caillon, and G Stephant, and F Jehl, and D Bugnon, and P Le Conte, and D Baron, and H Drugeon
February 1993, Antimicrobial agents and chemotherapy,
Y Q Xiong, and G Potel, and J Caillon, and G Stephant, and F Jehl, and D Bugnon, and P Le Conte, and D Baron, and H Drugeon
May 1985, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!